International Assets Investment Management LLC Buys Shares of 16,840 CureVac (NASDAQ:CVAC)

International Assets Investment Management LLC purchased a new stake in CureVac (NASDAQ:CVAC) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 16,840 shares of the company’s stock, valued at approximately $71,000.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of CureVac by 95.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after purchasing an additional 2,804 shares during the last quarter. Optiver Holding B.V. raised its holdings in shares of CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after acquiring an additional 6,571 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of CureVac in the third quarter valued at $74,000. Pathstone Family Office LLC acquired a new stake in shares of CureVac during the third quarter valued at $89,000. Finally, SG Americas Securities LLC boosted its stake in shares of CureVac by 157.4% during the third quarter. SG Americas Securities LLC now owns 31,497 shares of the company’s stock valued at $215,000 after acquiring an additional 19,259 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Price Performance

Shares of CVAC stock opened at $2.52 on Wednesday. The firm’s 50-day simple moving average is $3.02 and its 200-day simple moving average is $4.07. The company has a current ratio of 2.57, a quick ratio of 2.43 and a debt-to-equity ratio of 0.07. CureVac has a 1-year low of $2.21 and a 1-year high of $12.36.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CVAC. Guggenheim restated a “neutral” rating on shares of CureVac in a report on Friday, April 5th. SVB Leerink downgraded shares of CureVac from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $12.00 to $4.00 in a research note on Thursday, April 25th. Finally, Leerink Partnrs cut shares of CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, CureVac has a consensus rating of “Hold” and an average price target of $8.33.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.